All Outputs (2)

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells (2020)
Journal Article
Shah, M., Maroof, A., Gikas, P., Mittal, G., Keen, R., Baeten, D., …Roberts, S. J. (2020). Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open, 6(2), e001306. https://doi.org/10.1136/rmdopen-2020-001306

Objectives Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understo... Read More about Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.

Mapping human serum–induced gene networks as a basis for the creation of biomimetic periosteum for bone repair (2020)
Journal Article
Al Hosni, R., Shah, M., Cheema, U., Roberts, H., Luyten, F., & Roberts, S. (2020). Mapping human serum–induced gene networks as a basis for the creation of biomimetic periosteum for bone repair. Cytotherapy,

The periosteum is a highly vascularised, collagen-rich tissue that plays a crucial role in directing bone repair. This is orchestrated primarily by its resident progenitor cell population. Indeed, preservation of periosteum integrity is critical for... Read More about Mapping human serum–induced gene networks as a basis for the creation of biomimetic periosteum for bone repair.